Washington [US], March 10 (ANI): Researchers have found that modified vaccinia virus Ankara (MVA), a smallpox vaccine, can be further modified in a recombinant form to express the spike protein of the SARS-CoV-2 virus and that injection of one or two doses of the recombinant MVA protected transgenic mice from lethal infection, with vaccination also preventing detection of infectious SARS-CoV-2 in the mouse lungs.
The authors of the study were Ruikang Liu, Jeffrey L. Americo, Catherine A. Cotter, Patricia L. Earl, Noam Erez, Chen Peng, among others. The findings of the study were published in the journal PNAS.
Vaccines are required to control COVID-19 during the current pandemic and possibly afterward. Recombinant nucleic acids, proteins, and virus vectors that stimulate immune responses to the SARS-CoV-2 S protein have provided protection in experimental animal and human clinical trials, although questions remain regarding their ability to prevent spread and the duration of immunity.
The present study focuses on replication-restricted modified vaccinia virus Ankara (MVA), which has been shown to be a safe, immunogenic, and stable smallpox vaccine and a promising vaccine vector for other infectious diseases and cancer. In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited SARS-CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.
Modified vaccinia virus Ankara (MVA) is a replication-restricted smallpox vaccine, and numerous clinical studies of recombinant MVAs (rMVAs) as vectors for the prevention of other infectious diseases, including COVID-19, are in progress.
Here, the researchers characterize rMVAs expressing the S protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Modifications of full-length S individually or in combination included two proline substitutions, mutations of the furin recognition site, and deletion of the endoplasmic retrieval signal.
Another rMVA in which the receptor-binding domain (RBD) is flanked by the signal peptide and transmembrane domains of S was also constructed. Each modified S protein was displayed on the surface of rMVA-infected cells and was recognized by anti-RBD antibody and soluble hACE2 receptor.
Intramuscular injection of mice with the rMVAs induced antibodies, which neutralized a pseudovirus in vitro and, upon passive transfer, protected hACE2 transgenic mice from lethal infection with SARS-CoV-2, as well as S-specific CD3+CD8+IFNg+ T cells.
Antibody boosting occurred following a second rMVA or adjuvanted purified RBD protein. The immunity conferred by a single vaccination of hACE2 mice prevented morbidity and weight loss upon intranasal infection with SARS-CoV-2 3 wk or 7 wk later. One or two rMVA vaccinations also prevented the detection of infectious SARS-CoV-2 and subgenomic viral mRNAs in the lungs and greatly reduced induction of cytokine and chemokine mRNAs.
A low amount of virus was found in the nasal turbinates of only one of eight rMVA-vaccinated mice on day 2 and none later. Detection of low levels of subgenomic mRNAs in turbinates indicated that replication was aborted in immunized animals.
Recombinant DNA methods have revolutionized the engineering of vaccines against microbial pathogens, thereby creating opportunities to control the current COVID-19 pandemic.
The main categories of recombinant vaccines are protein, nucleic acid (DNA and RNA), virus vectors (replicating and nonreplicating), and genetically modified live viruses. Each approach has advantages and drawbacks with regard to manufacture, stability, cold-chain requirements, mode of inoculation, and immune stimulation. Recombinant proteins have been successfully deployed as vaccines against a variety of diseases.
DNA vaccines have been licensed for veterinary purposes, although none are in regular human use. Recently developed messenger RNA (mRNA) vaccines are in use for COVID-19 and are in preclinical development for other infectious diseases. At least 12 virus vector vaccines based on adenovirus, fowlpox virus, vaccinia virus (VACV), and yellow fever virus have veterinary applications, but, so far, only two have been marketed for humans, although numerous clinical trials, particularly with attenuated adenovirus and VACV, are listed online in ClinicalTrials.gov.
A variety of recombinant approaches utilizing the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; abbreviated CoV-2) as immunogen are being explored to quell the COVID-19 pandemic.
Vaccines based on mRNA and adenovirus vectors have demonstrated promising results in clinical trials and have received emergency regulatory approval. Other candidate CoV-2 vaccines, including ones based on vesicular stomatitis virus, an alphavirus-derived replicon RNA, an inactivated recombinant Newcastle Disease virus, and modified VACV Ankara (MVA) are at the early stages of evaluation.
Experiments with virus vectors for vaccination were carried out initially with VACV, providing a precedent for a multitude of other virus vectors.
The majority of current VACV vaccine studies employ the MVA strain, which was attenuated by more than 500 passages in chicken embryo fibroblasts during which numerous genes were deleted or mutated, resulting in an inability to replicate in humans and most other mammalian cells.
Despite the inability to complete a productive infection, MVA is capable of highly expressing recombinant genes and inducing immune responses. MVA is a licensed smallpox vaccine, and numerous clinical studies of recombinant MVA (rMVA) vectors are in progress or have been completed.
Protection has been obtained with MVA-based SARS-CoV-1 and Middle East respiratory syndrome CoV (MERS-CoV) in animals, and an MVA-based MERS-CoV vaccine was shown to be safe and immunogenic in phase 1 clinical trial.
Currently, two clinical trials for MVA-based CoV-2 vaccines are in the recruiting phase (ClinicalTrials.gov). Here, we show that one or two immunizations with rMVAs expressing the CoV-2 S proteins elicit strong neutralizing antibody responses, induce CD8+ T cells, and protect susceptible transgenic mice against a lethal intranasal challenge with CoV-2 virus, supporting clinical testing of related rMVA vaccines.
K18-hACE2 transgenic mice are imperfect models of human susceptibility to CoV-2, and the virus inoculum, which caused severe morbidity and death within 5 d to 6 d, is likely higher than occurs during human transmission.
The lack of signs of morbidity, failure to detect infectious CoV-2 in the lungs, and reduced levels of cytokines and chemokines in the lungs of vaccinated mice are consistent with the prevention of pathology, although the latter was not evaluated by pulmonary function tests or histological examination. (ANI)